Literature DB >> 2989490

Solubilization and characterization of putative alpha-2 adrenergic isoceptors from the human platelet and the rat cerebral cortex.

R S Kawahara, D B Bylund.   

Abstract

Alpha-2 adrenergic receptor isotypes have been proposed to explain several pharmacologic differences between rodent and nonrodent species. In support of this hypothesis, we found that the differences in the pharmacologic properties of rat cerebral cortex and human platelet alpha-2 adrenergic receptors were not due to 1) differential proteolysis of the receptor, 2) degradation of the ligand, 3) the detection of different affinity states or 4) the presence of different quantities of various affinity modulators. In an effort to test the hypothesis further we have characterized these prototype isoceptors in soluble form. Soluble receptors from both species showed the appropriate rank order of potencies for various adrenergic agonists and antagonists expected for an alpha-2 adrenergic receptor. The KD values for soluble human platelet and rat cerebral cortical alpha-2 receptors were 4.2 and 5.9 nM, respectively. The species differences in the affinities of prazosin and oxymetazoline were retained upon solubilization. Both soluble receptors were insensitive to modulation by guanine nucleotides, indicating uncoupling from the inhibitory regulatory subunit Ni. Sucrose density gradient centrifugation of soluble receptors did not indicate any significant molecular size differences.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989490

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  [3H]L-654,284 as a probe of the central alpha 2 adrenoceptor.

Authors:  W C Randall; J R Huff; J P Vacca; J P Guare; R Chen; A Rosegay; J J Baldwin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

2.  Photoaffinity labeling of the porcine brain alpha 2-adrenergic receptor using a radioiodinated arylazide derivative of rauwolscine: identification of the hormone-binding subunit.

Authors:  S M Lanier; R M Graham; H J Hess; A Grodski; M G Repaske; J M Nunnari; L E Limbird; C J Homcy
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  Differences between the alpha 2-adrenoceptor in rat submaxillary gland and the alpha 2A-and alpha 2B-adrenoceptor subtypes.

Authors:  A D Michel; D N Loury; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

4.  Agonist binding at alpha 2-adrenoceptors of human platelets using 3H-UK-14,304: regulation by Gpp(NH)p and cations.

Authors:  J Schloos; A Wellstein; D Palm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

5.  Pharmacological profile of a new potent and specific alpha 2-adrenoceptor antagonist, L-657,743.

Authors:  D J Pettibone; B V Clineschmidt; V J Lotti; J J Baldwin; J R Huff; W C Randall; J Vacca; S D Young
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-08       Impact factor: 3.000

6.  Heterogeneity of alpha 2-adrenoceptors in rat cortex but not human platelets can be defined by 8-OH-DPAT, RU 24969 and methysergide.

Authors:  C M Brown; A C MacKinnon; J C McGrath; M Spedding; A T Kilpatrick
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

7.  Assessment of imiloxan as a selective alpha 2B-adrenoceptor antagonist.

Authors:  A D Michel; D N Loury; R L Whiting
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

8.  Alpha-1 and alpha-2 adrenoceptor binding in cerebral cortex: competition studies with [3H]prazosin and [3H]idazoxan.

Authors:  T A Reader; R Brière; L Grondin
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

9.  Comparison of potency of alpha 2-adrenoceptor antagonists in vitro: evidence for heterogeneity of alpha 2-adrenoceptors.

Authors:  V A Alabaster; R F Keir; C J Peters
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.